The purpose of the study was to study the dynamics of the incidence of thyroid cancer in the female population of the Altai Territory during the period of 1992-2016. Studies were performed with the use of data of the patient register of thyroid cancer, including information on 3026 women, with the use of methods of modern medical statistics. Intensive and standardized indices were calculated for the female population, resided near to traces of nuclear explosions executed at the Semipalatinsk test site, in the zone of the most significant radiation doses (the Main group). As a comparison, incidence rates of the remaining population of the Altai Territory (the Comparison group) and average values for the region were used. The article presents results of a descriptive epidemiological study of the incidence of thyroid cancer in the Altai Territory over 25 years (1992-2016). The results of the probabilistic association of the incidence of thyroid cancer with the ionizing radiation factor due to nuclear tests at the Semipalatinsk test site were obtained. The dynamics of the incidence of thyroid cancer by the data for five-years periods (averaged data): 1992-1996; 1997-2001; 2002-2006; 2007-2011 and 2012-2016 was studied in various territories of the Altai Territory: both on the traces of nuclear explosions - the main group, and in the rest territory (the comparison group), indices of average values for the regions. There were revealed the dynamics of the incidence of thyroid cancer in tens of years after nuclear tests in the population living in the zone with the most significant doses of radiation and its gradual decrease, due to rehabilitation measures. New approaches to the formation of high cancer risk groups for thyroid cancer in the Altai Territory are substantiated.

e11047 Background: MPC represents the interest for their prognosis and more effective treatment. The objectives of our research was to investigate clinical and genetic characteristics of MPC among women with familial and sporadic BC. Methods: The research is based on data of 1407 Caucasian women with BC aged 20-79 years (555-familial BC, 852– sporadic BC), control group consisted of 1006 women without a history of cancer. In all groups were analyzed more than 100 phenomic and genotypic factors. Processing of the results was performed using modern methods of biomedical statistics. Statistically significant differences taken at p<0.05. Genotyping was carried out by real-time PCR using competitive Taq-Man probes or with allele-specific PCR using SYBR Green intercalating dye. Results: Specific weight of MPC in group of familial BC [18,0% (14,74-21,26] was higher than in group of sporadic BC [2,0% (1,04-2,96)]. Among women with familial BC with MPC premenopause status met more rapidly [10,1 (4,06-16,14)] than in the group of sporadic BC with MPC [5,0 (1,26-8,74)]. Specific weight of BRCA-negative cases and FGFR-mutations were higher in familial group with MPC than in the group of sporadic BC with MPC [68,7% (59,38-78,02) against 40,0% (18,10-61,90); 3,0% (0,42-6,42) against 35,0% (13,66-56,34)]. Patients with triple negative and HER2neu positive BC met more frequently in familial group with MPC than in the group of sporadic BC with MPC. Reproductive factors such as obesity, aborts and others also had significance. Conclusions: Clinical and genetic characteristics of MPC in group of familial BC have different characters as against as group of sporadic BC.

e22223 Background: Hereditary breast carcinomas that are attributable to BRCA1 mutations have their own morphological and immunohistochemical characteristics. This study was aimed to analyze the level of expression of steroids (estrogen and progesterone) and HER2-neu receptors in BRCA1 associated breast cancer. Methods: DNA patterns from 264 patients with hereditary breast cancers (breast cancer diagnosed at the age under 40; bilateral breast cancer; combination of breast and ovarian cancers; 2 and more breast cancers in blood relatives). All the patients were residents of the Altai Territory. BRCA1 gene mutations were registered in 34 patients (12.9%): 5382insC gene mutation - in 28 patients; 300A/C - in 2 patients; 4153del - in 3 patients; 185del - in 1 patient. The frequency of the BRCA1 5382insC allele mutation was 7.3; 300A/C - 0.52; 4153del - 0.26; 185del - 0.83. Immunohistochemical characteristics of BRCA1-associated breast tumors tissue from these patients were investigated. Results: 32 BRCA1-associated breast carcinomas were estrogen receptor- negative; 1 - week positive (H-score 50–100); 1 - moderate positive (H- score 100–200). 33 BRCA1-associated breast carcinomas were progesterone receptor- negative; 1 - positive (H-score 200 and more). HER2-negative were 31 BRCA1-associated breast carcinomas; 2 were week positive (HER2-neu +); 1 - was moderate positive (HER2-neu ++). Conclusion: BRCA1-associated beast carcinomas have been found to be more frequently estrogen receptor-, progesterone receptor-, and HER2- negative. These data show that hereditary breast cancer associated with BRCA1 gene mutations poses poor prognosis. No significant financial relationships to disclose.

The incidence of homozygote deletion of glutathione S-transferase genes M1 and T1 (null genotypes; or GSTM1“-” and GSTT1“-”) was studied in breast cancer patients living in Altai Krai. DNA was isolated from blood samples of 695 breast cancer patients (291 patients with familial cancer and 404 patients with sporadic cancer) and 263 women without history of tumor diseases. The frequency of GSTM1“-” and с GSTT1“-” genotypes was estimated in breast can cer patients (47.2 and 19.1%, respectively) and non-cancer participants (46.8 and 19.0%, respectively). No differences were found in the frequency of genotypes. The frequency of genotype combination GSTM1“-”+GSTT1“-” in patients with sporadic breast cancer (11.6%, 47 of 404 patients) was higher than in the control (6.1%, 16 of 263 patients; OR=2.03; 95% CI=2.09-3.83; p=0.02). The genotype frequency of genes in the control group did not differ from that in European residents of the Caucasian race.

The incidence of MnSOD genotypes in residents of the Altai Region suffering from breast cancer and individuals without a history of cancer corresponded to the Hardy-Weinberg equilibrium. No association of MnSOD with the incidence of sporadic breast cancer was detected. No association of MnSOD, tobacco smoking, or menopausal status, on the one hand, and breast cancer development, on the other, was detected.

22133 Background: Many investigators consider MPT typical for patients from families with cancer history, but the characteristics of polyneoplasia in this group of patients are still to be analyzed. Methods: The registry of patients from “cancer”-families (who had 3 and more relatives by blood with cancers), formed in Altai oncological centre, included 1986 patients (196 male and 1790 female) ages 28 to 74. All of them were kept under medical observation according to in-house designed algorithms. MPT in this group were analyzed as compared to general population of the Altai territory (the data of the Altai territory cancer registry). Results: MPT were registered in 28 patients (27 female and 1 male) from “cancer”-families (all in early stages). The proportion of patients with MPC in this group was significantly higher (1.4%) than in general population (0.66%). The average age of the patients at the moment of first cancer revealing (47.6 years) was significantly lower than the same in general population (59.7 years). In the group of patients from “cancer”-families with MPT there were more patients in younger ages as compared to the same in general population: at the age before 29 - 3.6% and 2.6%, respectively; 30–39 years old - 21.4% and 4.1%, respectively; 40–49 years old - 32.1% and 13.8%, respectively. 4 patients from “cancer”-families had synchronous MPT, 24 - metachronous. The mean interval between the first and the second cancer was 6,6 years. Combinations of the tumours of reproductive system (breast, ovarian cancer, cancer of cervix and corpus uteri) and thyroid cancer were the most frequent. Conclusion: In the group of patients from “cancer”-families MPT were registered more often, than in general population and in younger ages. Patients with MPT from this group most often had cancers of reproductive system. Medical observation of this group of patients organized in proper way made it possible to predict and reveal cancers in early stages. No significant financial relationships to disclose.

22196 Background: Skin cancer is the second by the frequency in the structure of cancer incidence in the Altai territory. According to the State direction in Russian Federation basal cell carcinoma of skin is the reported site of cancer, it is subjected to the registration by cancer registries, but at the absence of recurrence or progression should be stricken off the registry when 5 year after the treatment pass. Annually 500 patients treated for basal cell carcinoma of skin are stricken off the Altai Territory Cancer Registry (ATCR). Methods: The study aimed to estimate the periods of time till second primary cancer appeared in patients treated for basal cell carcinoma of skin and to determine the necessary duration of regular medical check-up of these patients. The data of ATCR were analyzed. Results: Among patients with multiple primary tumours (MPT) registered in the Altai territory in 1995–2005 skin was the most frequent site of the first cancer (744 patients - 20.9%). Among these patients 647 ( 86.9%) had basal cell carcinoma. 20.5% of them (133 patients) developed the second tumour synchronously and 79.5% (514 patients) had metachronous MPT. In the whole the period between the first and the second tumour was less then 5 years in 411 patients (63.5%). Thus, 103 (16.0%) patients developed the second tumour after the moment they were stricken off the registry (with the max interval of 30 years). Among the sites of the second cancer the most frequent were skin (22.4%), lung (12.8%), stomach (7.5%), breast (5.8%) and lip (5.1%). Conclusion: Taking into account high frequency of the second cancer development in patients treated for basal cell carcinoma of skin, they are subjected to lifelong regular medical check-up. No significant financial relationships to disclose.

15105 Background: Liver metastases is frequent cause of death of patients with colorectal cancer during the first 2 years. Chemotherapy and liver surgery do not have significant influence on survival. Methods: To improve the effectiveness of treatment of patients with colorectal liver metastases a new method of neo-adjuvant chemo- and biotherapy was designed in Altai oncological centre. 26 patients underwent combined therapy for colorectal cancer with liver metastases. A single solitary liver metastasis was diagnosed in 10 patients, multiple metastases - in 16. 14 patients had bilobed involvement. The largest of metastases were from 4.5 to 25 cm in diameter. 4 patients got 3 courses of neo-adjuvant chemotherapy FOLFOX 6 followed by three-hour infusion of bevacizumab (Avastin) 5mg/m2 via hepatic artery. 22 patients got chemotherapy in the same regimen but without bevacizumab. In a month all the patients had the surgery for liver metastases: 11 patients underwent hemihepatectomy, 1 - extended hemihepatectomy, 4 - hemihepatectomy with resection of other lobe of liver, 1 - limited resection of the liver. Then the patients got the same chemo- and biotherapy. Results: The effectiveness of the preoperative therapy was: 15.4% - partial response, 53.8% - stable disease, 30.8% - tumour progression. 11 patients had postoperative complications, 1 - died of them. None of those who got Avastin before surgery had complications. To the end of he first year all the patients survived (100%). 2-years survival for the present moment amounted 61.0±18.0% (Kaplan-Meier method). None of those who got Avastin in the neo-adjuvant regimen progressed. Conclusion: These data suggest that intraarterial chemo- and biotherapy in neo-adjuvant regimen improved the results of the surgery for colorectal liver metastases and served as preventative measure for recurring dissemination of the tumour in the residuary lobe of liver in the nearest 2 year, and did not entail increasing of complications and lethality. No significant financial relationships to disclose.